<DOC>
	<DOCNO>NCT00436007</DOCNO>
	<brief_summary>This study do assess possibility potential integration malaria vaccine EPI regimen . It evaluate whether malaria vaccine safe immunogenic infant age 6 10 week first dose , co-administered EPI vaccine antigen . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Safety Immunogenicity Study GSK Biologicals ' Malaria Vaccine 257049 , When Incorporated Into EPI Regimen</brief_title>
	<detailed_description>Two vaccination schedule study , constitute two alternative three dose regimen malaria candidate vaccine 257049 integration EPI . The co-administered EPI vaccine include GSK Biologicals ' Tritanrix™-HepB/Hiberix™ , measles vaccine ( depend supply availability ) , Aventis Pasteur 's Yellow Fever vaccine Stamaril™ GSK Biologicals ' Oral Polio vaccine Polio Sabin™ . Tuberculosis vaccine ( Bacillus Calmette Guerin , BCG ) administer accord national medical practice administer part protocol , document .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female infant 6 10 week age time first vaccination . Signed thumbprinted informed consent obtain parent ( ) /guardian ( ) child . Where parent ( ) /guardian ( ) illiterate , consent form countersign witness . Subjects receive one previous dose OPV BCG . Subjects born normal gestation period ( 36 42 week ) . Acute disease time enrolment . Serious acute chronic illness determine clinical physical examination laboratory screen test . Laboratory screen test range , specifically : ALT creatinine acceptable limit ; Hemoglobin , Platelet count Total white cell count acceptable limit . Previous vaccination diphtheria , tetanus , pertussis ( wholecell acellular ) , Hemophilus influenzae type b hepatitis B vaccine . BCG administration within one week propose administration study vaccine . OPV administration within four week propose administration study vaccine . Planned administration/administration vaccine foreseen study protocol within 30 day first dose vaccine ( ) . Use investigational nonregistered drug vaccine within 30 day precede first dose study vaccine , plan use study period . Administration immunoglobulins , blood transfusion blood product since birth first dose study vaccine plan administration study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Simultaneous participation clinical trial . Twins ( avoid misidentification ) . Maternal death . History allergic reaction ( significant IgEmediated event ) anaphylaxis previous immunization . History allergic disease reaction likely exacerbate component vaccine . Any finding investigator feel would increase risk adverse outcome participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Africa</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Malaria</keyword>
</DOC>